The Week

CME Group fell 2.04% this week to close at $275.54 on Friday, underperforming the S&P 500, which declined 0.8%, by roughly 1.24 percentage points. It was a soft, four-session stretch. The stock opened Tuesday at $280.78 and drifted lower, closing Wednesday at $274.70. Thursday’s session touched an intraday low of $271.295, before a modest Friday rebound. Weekly amplitude was about 3.46%, and average daily volume came in more than 30% below the prior median, pointing to a cautious tape.

Key Events

Business news was fairly active. Early in the week, CME Group reported a new record for FX open interest, then announced a partnership with EEX to transition its European dairy futures business. The company also outlined expansion plans around single-stock futures and US Treasury clearing, with CME Securities Clearing set to launch on December 7. On the regulatory front, the CFTC sought dismissal of CME’s lawsuit over Kalshi bitcoin perpetual futures, while Kalshi gained CFTC approval to launch gold and silver perps, underscoring the competitive push among exchanges. CME also announced new senior leadership appointments, and CEO Terrence A. Duffy sold $4.12 million in Class A common shares after the week ended. CalSTRS reported a position in CME during the period.

Analyst Ratings

Coverage of CME totals 17 institutions: 4 rate it buy, 3 rate it overweight, 6 rate it hold, 2 rate it underweight, and 1 rates it sell, with 1 holding no clear view. The consensus rating is hold, and the consensus target price of $283.60 sits about 2.93% above the latest price. Targets range from $230 to $330, a wide spread that signals meaningful divergence among brokers. Within the financial exchanges and data industry, CME ranks 7th out of 26 names, placing it in the upper-middle tier.

The Week Ahead

Macro data picks up next week. On September 15, the New York Fed manufacturing index is due, followed on September 16 by retail sales, retail sales ex-autos, import prices, the NAHB housing market index, and weekly EIA crude inventory figures. Traders nudged up bets on a Fed rate hike during the week, so these releases may shape rate expectations. On the company side, CME’s fiscal Q3 2026 results are scheduled for October 21 before the market opens, with consensus estimates at $2.8177 EPS and $1.693 billion in revenue. The focus is likely to remain on clearing expansion and derivatives volume trends.

In Short

CME shares pulled back this week while the business continued to widen its footprint, from a record in FX open interest to the dairy futures transition and a firm date for US Treasury clearing. Analyst positioning looks balanced overall: the consensus rating is hold, and the target price is only marginally above spot with a wide high-low range. Valuation is not extreme at roughly 23.23x earnings and 3.740x book. The signal is mixed rather than directional. The next leg depends on how retail sales and rate expectations develop, and whether derivatives volume and clearing expansion show up in the coming earnings report.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.